Executive Director, DCTL, BTK Degrader

BeiGene continues to grow at a rapid pace with challenging and exciting opportunities for experienced professionals. When considering candidates, we look for scientific and business professionals who are highly motivated, collaborative, and most importantly, share our passionate interest in fighting cancer.

BeiGene is seeking a Development Core Team Leader (DCTL) for the BTK Degrader, Global Hematology. This individual will have clinical and drug development experience and will lead the BTK Degrader within our Hematology organization. The DCTL will serve as the strategic clinical leader, shaping and driving the global development strategy for this asset within specific disease domains.

Reporting directly to the Vice President of Hematology, the DCTL will lead a global, cross-functional team committed to advancing innovative therapies.

This role is crucial for advancing BeiGene’s pipeline of innovative therapies and requires a visionary leader with deep expertise in drug development and a passion for improving patient outcomes on a global scale. As the leader of the Development Core Team (DCT), the DCTL will be responsible for the strategic vision, development, and execution of clinical programs. The role will collaborate closely with cross-functional teams, including the GPTL, Regulatory Affairs, Clinical Operations, Commercial, and other key stakeholders, to ensure that development programs meet corporate goals and are aligned with BeiGene’s mission to deliver transformative therapies to patients.

About BGB16673 
BGB16673 is an orally available Bruton’s tyrosine kinase (BTK) targeting chimeric degradation activation compound (CDAC) designed to induce degradation of wildtype and multiple mutant forms of BTK, including those that commonly confer resistance to BTK inhibitors in patients who experience progressive disease. 

Key Roles & Responsibilities:

• Strategic Leadership: Define and oversee the global clinical development strategy for the BTK Degrader, translating corporate objectives into actionable program-level strategies that integrate scientific, clinical, operational, and regulatory considerations.
• Program Excellence: Continuously refine development plans in response to emerging data and competitive dynamics, ensuring the program’s alignment with evolving business priorities. Craft and maintain an integrated development timeline with clearly defined milestones and critical decision points.
• Collaborative Partnership: Partner with the Global Program Team Leader (GPTL) to craft and execute disease area strategies, optimizing the asset's lifecycle and maximizing its potential impact. Facilitate seamless collaboration across cross-functional teams to support the successful registration and commercialization of the asset.
• Risk Management: Lead proactive risk management efforts, developing and implementing mitigation strategies to navigate complex clinical and regulatory environments.
• Clinical Oversight: Provide visionary leadership and medical oversight for …